Fireside Chat: Building the Future from a Distinguished Tenure in CMC

  • Introducing Prime Medicine and its vision for the future of medicine
  • How are we thinking about the inclusion of novel types of automation into molecular medicine workflows?
  • Examining how we view Talent in the emergent technology space, and how do we best deploy remote and hybrid work?
  • Historically, pharmaceutical manufacturing leaders were predominantly men; however, many important CMC leadership positions are now held by women. Why is this the case, and how do we sustain this pattern?
  • What are the most significant learnings from having achieved success in licensing autologous cell therapies?

Ann Lee
Chief Technical Officer

Prime Medicine

Ann Lee, PhD, is the Chief Technical Officer of Prime Medicine. Ann is an accomplished biotech executive with extensive experience and accomplishments in vaccines, biologics, small molecules and cell therapy development and manufacturing. She brings a passion for helping patients, innovating new technologies, and developing employees. Over the course of her career, she has contributed to the licensure and commercialization of 25 new vaccines and medicines, with the most recent being two CAR T cell therapies.

Ann recently worked at BMS, which acquired Celgene and Juno Therapeutics. Ann joined Juno Therapeutics in 2017 as Executive VP of Technical Operations to work in the new field of cell and gene therapy. She built the global Cell Therapy Development and Operations organization responsible for developing new manufacturing processes and technologies, manufacturing, quality assurance, designing new facilities, and creating the global supply chain network and digital systems to deliver these autologous products.

Ann was at Genentech in 2005 as VP of Process R&D and became SVP and Head of Global Technical Development at Roche in 2009. She was responsible for delivering Roche’s global R&D pipeline, as well as tech transfer and technical support for all commercial products. She was a member of corporate strategic portfolio governance committees and worked extensively cross-functionally as well as with external partners across the globe.

Prior to Genentech, Ann joined Merck Research Laboratories, where she advanced through several leadership positions in vaccine development over 14 years. She then became Vice President of Chemical Technology and Engineering in the Manufacturing Division at Merck, overseeing process engineering and technical operations at 10 chemical sites around the world.

Ann is a member of the National Academy of Engineering, a Fellow of the American Academy of Arts and Sciences, and a Fellow of the American Institute of Medical and Biological Engineering. She is the recipient of many scientific and engineering awards and has served on several professional, academic and company boards. She holds a B.S. in chemical engineering from Cornell University, and a Ph.D. in biochemical engineering from Yale University.


Alison Moore
Chief Technology Officer


Dr. Alison Moore is Chief Technical Officer at Allogene Therapeutics. Prior to this role, Moore served as Senior Vice President, Process Development, in Amgen Operations. Moore was previously vice president, Process and Product Engineering (P&PE), where she was responsible for Process Development, Clinical Operations and Global Operations Planning. Moore served as vice president, Corporate Manufacturing, overseeing Supply Chain, Contract Manufacturing, Global Distribution, Manufacturing Technologies, and Operations Risk Management. Before taking on this position, she was vice president, Site Operations at Amgen’s Fremont, California, manufacturing facility (AFR).

Before heading up the AFR facility, Moore was a director in Chemistry, Manufacturing and Controls Regulatory Affairs at Genentech. Prior to her time at Genentech, Moore had previously spent nine years at Amgen in various positions of increasing responsibility within the Process Development organization.

Moore holds a Ph.D. in Cell Biology from Manchester University, England, and a bachelor’s in Pharmacology with Honors from Manchester University, England. Following her doctoral degree work at Manchester University, she was a Postdoctoral Research Fellow at the Medical University of Lübeck, Germany, and at Genentech.